Home > Insider Trading > Filing (0001181431-14-021281)

Filing Details

Accession Number:: 0001181431-14-021281
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-05-27 16:20:14
Reporting Period:: 2014-05-22

Filing Date:: 2014-05-27
Accepted Time:: 2014-05-27 16:20:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1410939	Ophthotech Corp.	OPHT	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1367381	Sv Life Sciences Fund Iv, L.p.	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No
1392309	Sv Life Sciences Fund Iv Strategic Partners, L. P.	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No
1422339	Svlsf Iv, Llc	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No
1422340	Sv Life Sciences Fund Iv (Gp), L.p.	One Boston Place 201 Washington Street, Suite 3900 Boston MA 02108	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2014-05-22	34,000	$37.57	5,045,458	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2014-05-22	34,000	$37.57	5,045,458	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2014-05-22	33,061	$37.57	4,906,169	No	4	S	Direct
Common Stock	Disposition	2014-05-22	939	$37.57	139,289	No	4	S	Direct
Common Stock	Disposition	2014-05-23	76,150	$38.34	4,969,308	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2014-05-23	76,150	$38.34	4,969,308	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2014-05-23	74,048	$38.34	4,832,121	No	4	S	Direct
Common Stock	Disposition	2014-05-23	2,102	$38.34	137,187	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Direct
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Direct
No	4	S	Direct

Footnotes

These shares are owned directly by SV Life Sciences Fund IV, L.P. ("SVLS IV LP") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners"). SV Life Sciences Fund IV (GP), L.P. ("SVLS IV GP"), the general partner of SVLS IV LP and Strategic Partners, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLS IV GP disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein.
These shares are owned directly by SVLS IV LP and Strategic Partners. SVLSF IV, LLC, the general partner of SVLS IV GP, may be deemed to share voting and dispositive power over the shares held by SVLS IV LP and Strategic Partners. SVLSF IV, LLC disclaims beneficial ownership of shares held by SVLS IV LP and Strategic Partners except to the extent of any pecuniary interest therein.
These shares are held directly by SVLS IV LP.
These shares are held directly by Strategic Partners.
SVLS IV LP and Strategic Partners (each a "Fund", or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.795, inclusive. The reporting person undertakes to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.765 to $38.66, inclusive. The reporting person undertakes to provide to the Registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.